.ANALYSIS FEATURE.16 October 2024.
In the NIAGARA trial, the add-on of perioperative durvalumab to conventional therapy for muscle-invasive bladder cancer cells strengthened event-free as well as overall survival, denoting a brand new procedure option for this ailment.